Compare LYFT Inc (LYFT) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Novartis AG — how do they compare? LYFT Inc trades at $16.16 (market cap $5.90B), while Novartis AG trades at $142.04 (market cap $274.00B). The key difference: Novartis AG is far larger — about 46.4× LYFT Inc's market cap, and Novartis AG pays a 3.31% dividend while LYFT Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 47 Days and Novartis AG for 82 Days on average.
| LYFT | NVS | |
|---|---|---|
Market Cap | $5.90B | $274.00B |
Volume | 9,741,129 | 1,852,137 |
Sector | Technology | Health |
52-Week High | $24.57 | $168.62 |
52-Week Low | $12.65 | $121.80 |
Typical Hold Time | 47 Days | 82 Days |
Enterprise Value | $5.37B | $315.32B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft trades at $16.13, up 2.35% on the day, with a bullish technical signal from moving averages but a neutral stance from oscillators. The company reported strong revenue growth to $6.32B in 2025 and a net income of $2.84B, though recent quarterly EPS results have missed expectations. Positive developments include European expansion and a partnership with Sphere, while a $272.5M legal settlement poses a headwind.
The outlook is mixed; low P/E and P/S ratios suggest undervaluation, and analyst consensus targets $18.07, but execution risks and competitive pressures remain. Earnings consistency is key for sustained upside, with the stock offering value if growth momentum continues despite near-term volatility.
Novartis (NVS) trades at $143.11, up 1.65% with mixed technical signals showing neutral momentum. The company maintains strong profitability with 22.5% net margins and recently announced a $7.8B licensing deal with China's Abogen. Recent earnings show two beats and one miss in the last three quarters, with Q3 2026 results pending. The stock trades below the consensus price target of $146, suggesting modest upside potential from current levels.
Novartis presents a balanced investment case with strong cash flow generation and profitability offset by recent clinical setbacks and M&A scrutiny. The $7.8B Abogen partnership expands the autoimmune pipeline, but investors face risks from patent cliffs and drug development failures. Analyst consensus leans cautious with 68% hold ratings, reflecting uncertainty around pipeline execution amid ongoing strategic repositioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
